ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ENTX Entera Bio Ltd

2.26
-0.05 (-2.16%)
May 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 101,079
Bid Price 2.26
Ask Price 2.33
News -
Day High 2.32

Low
0.52

52 Week Range

High
3.35

Day Low 2.19
Share Name Share Symbol Market Stock Type
Entera Bio Ltd ENTX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.05 -2.16% 2.26 17:58:09
Open Price Low Price High Price Close Price Previous Close
2.24 2.19 2.32 2.32 2.31
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
583 101,079 US$ 2.26 US$ 228,160 - 0.52 - 3.35
Last Trade Type Quantity Price Currency
17:53:38 4 US$ 2.27 USD

Entera Bio Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
82.32M 35.48M - 49k -8.89M -0.25 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Entera Bio News

Date Time Source News Article
5/15/202407:00GlobeNewswire Inc.Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical..
5/13/202406:00GlobeNewswire Inc.Entera Bio to Present Phase 1 Data from First-in-Class,..
5/10/202415:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/10/202415:10Edgar (US Regulatory)Form 8-K - Current report
5/10/202415:10GlobeNewswire Inc.Entera Bio Reports Q1 2024 Financial Results and Provides..
4/08/202407:30GlobeNewswire Inc.Entera Bio Announces Publication of Oral PTH(1-34) Peptide..
3/26/202407:30GlobeNewswire Inc.Entera Bio Announces Key Regulatory Milestone for Oral..
3/20/202407:00GlobeNewswire Inc.Entera Bio Announces Robust Pharmacokinetic Data for..
3/08/202415:25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee..
3/08/202415:12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K..
3/08/202415:10Edgar (US Regulatory)Form 8-K - Current report
3/08/202415:05GlobeNewswire Inc.Entera Bio Announces Full Year 2023 Financial Results and..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ENTX Message Board. Create One! See More Posts on ENTX Message Board See More Message Board Posts

Historical ENTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.602.602.16012.35138,983-0.34-13.08%
1 Month1.972.7681.84392.30176,3880.2914.72%
3 Months1.373.351.252.15265,0630.8964.96%
6 Months0.703.350.521.79175,8021.56222.86%
1 Year0.96623.350.521.61104,4881.29133.91%
3 Years3.208.680.47225.10362,966-0.94-29.38%
5 Years3.7010.160.47224.53706,735-1.44-38.92%

Entera Bio Description

Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The company's product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The company recently completed the phase 2 study for EB613. The company also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.

Your Recent History

Delayed Upgrade Clock